ADELE
01 Jun 2021
Trial Summary
Adjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk endometrial cancer (ADELE): a randomised phase 2 trial.
Acronym:
ADELE
ACTRN/NCT /ethics:
ACTRN12621000273886
Scientific title:
Adjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk endometrial cancer (ADELE): a randomised phase 2 trial.
Sponsor / Cooperative group:
ANZGOG/NHMRC
Trial & Patient Characteristics
| Cancer Type | Gynaecological |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Female |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2021-12-13 |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Dr Sid Selva |
| Recruitment Status | Not Yet Recruiting |
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Hannah Adelson |
| Hannah.adelson@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Dr Ganessan Kichenadasse |
| Recruitment Status | Recruiting |